This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Owens & Minor Shares Surge 39% on Earnings Beat and Growth Plans
by Zacks Equity Research
OMI's shares witnessed a massive uptick after the company posted stronger-than-expected Q4 earnings. Its strategic focus on Patient Direct and the Rotech acquisition indicates long-term shareholder value.
Earnings Estimates Moving Higher for Masimo (MASI): Time to Buy?
by Zacks Equity Research
Masimo (MASI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
GEHC Stock May Rise on Freelium Magnet Launch, Boosts MR Access
by Zacks Equity Research
GE HealthCare unveils Freelium, a next-gen sealed magnet platform designed to revolutionize MR imaging with minimal helium usage.
Quest Diagnostics Stock Jumps 38% in a Year: What's Behind the Surge?
by Zacks Equity Research
DGX outperforms the industry and the S&P 500 composite's gain in the past year, driven by strong core performance and contributions from acquisitions.
Here's Why Masimo (MASI) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here is Why Growth Investors Should Buy Masimo (MASI) Now
by Zacks Equity Research
Masimo (MASI) possesses solid growth attributes, which could help it handily outperform the market.
GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock?
by Zacks Equity Research
Glaukos reported robust fourth-quarter revenues, but shares plunged 24.8% post-earnings. Can expanding iDose TR adoption and global growth offset competitive pressures and valuation concerns in 2025?
CLOV Q4 Earnings Beat Estimates, Sales Miss, Membership Rises
by Zacks Equity Research
Clover Health's fourth-quarter 2024 results continue to benefit from the strength of its strong member retention. Strong revenue outlook bodes well.
Is PAHC Stock a Smart Addition to Your Portfolio Right Now?
by Zacks Equity Research
Phibro's robust performance in the Animal Health business and prospects in the emerging markets are highly encouraging.
Masimo (MASI) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Masimo (MASI) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom
by Urmimala Biswas
FMS, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.
Can ITGR Stock's Growth Drivers Offset Rising Risks in 2025?
by Zacks Equity Research
Integer Holdings projects 8-10% sales growth in 2025, driven by acquisitions and high-demand medical technologies. But, can it overcome tariff and margin pressures?
PDCO Q3 Earnings & Sales Miss Estimates, Margins Contract
by Zacks Equity Research
Patterson Companies' overall top-line figure for the third quarter of fiscal 2025 reflects weak segmental performance.
Fresenius Medical Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
FMS' fourth-quarter results showcase a strong segmental performance along with providing full year 2025 outlook for revenue growth and operating income.
INGN Stock Gains Following Q4 Earnings Beat, Adjusted Gross Margin Up
by Zacks Equity Research
Inogen's overall fourth-quarter 2024 results continue to gain from higher business-to-business sales.
MASI Stock Gains Following Q4 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Masimo's fourth-quarter 2024 results continue to benefit from the strength in its Healthcare and Non-healthcare businesses.
Masimo (MASI) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Masimo (MASI) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Masimo (MASI) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 20.81% and 0.78%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Tempus Stock Falls as Q4 Earnings & Revenues Miss Estimates
by Zacks Equity Research
TEM's fourth-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.
The Zacks Analyst Blog Highlights Fresenius Medical, Masimo, Merit Medical Systems and Inogen
by Zacks Equity Research
Fresenius Medical, Masimo, Merit Medical Systems and Inogen are included in this Analyst Blog.
DENTSPLY SIRONA to Post Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
XRAY is likely to have faced a tough fourth quarter with Byte's revenue loss, weak U.S. equipment demand and implant pressures.
What to Expect From These 4 Medical Device Stocks in Q4 Earnings?
by Indrajit Bandyopadhyay
Here is a sneak peek into how four Medical Device stocks, namely FMS, MASI, MMSI and INGN, are expected to fare in their quarterly results, slated to be released tomorrow.
Bio-Techne Stock Set to Benefit From Expansion of RNAscope Menu
by Zacks Equity Research
TECH unveils the RNAscope Probes menu for human and mouse transcriptome to advance spatial biology.
GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline
by Zacks Equity Research
Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.
BAX Stock Surges Following Q4 Earnings & Sales Beat, Margins Decline
by Zacks Equity Research
Baxter reports better-than-expected fourth-quarter results. However, the company's gross and operating margins contract. Shares rise in pre-market.